MBC94, a conjugable ligand for cannabinoid CB 2 receptor imaging

Area of Science:

• Neuroscience
• Molecular Imaging
• Pharmacology

Background:

• Cannabinoid Receptor Type 2 (CB2) is a key target for neuroimaging due to its low expression in healthy brains and upregulation in neuroinflammation.
• CB2 receptor expression increases in microglial cells and infiltrating immune cells during conditions like cerebral ischemia, injury, and neuroinflammatory diseases.
• Targeting CB2 receptors offers a noninvasive method for visualizing brain inflammation and assessing therapeutic responses.

Purpose of the Study:

• To synthesize a novel, conjugable CB2 receptor ligand (mbc94) for developing targeted imaging agents.
• To create a near-infrared (NIR) imaging probe (NIRmbc94) by labeling mbc94 for CB2-specific visualization.
• To evaluate the specificity and efficacy of NIRmbc94 for labeling CB2-expressing cells.

Main Methods:

• Synthesis of a novel CB2 receptor ligand, mbc94, featuring a terminal amino group for conjugation.
• Conjugation of mbc94 with a near-infrared (NIR) dye to create the imaging probe NIRmbc94.
• In vitro fluorescence imaging and competition studies to assess probe specificity.

Main Results:

• The novel ligand mbc94 was successfully synthesized with a functional group for easy conjugation.
• The developed NIR-labeled probe, NIRmbc94, was created for targeted imaging of CB2 receptors.
• Preliminary in vitro results demonstrated that NIRmbc94 specifically binds to and labels cells expressing CB2 receptors.

Conclusions:

• NIRmbc94 is a promising novel imaging agent for specifically targeting CB2 receptors.
• This probe has potential applications in noninvasive neuroinflammation imaging and monitoring therapeutic efficacy.
• Further studies are warranted to validate NIRmbc94's utility in vivo for neurological conditions.